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Mass spectrometry (MS)-based proteomics has developed into a battery of approaches that is exceedingly adept at
identifying with high mass accuracy and precision any of the following: oxidative damage to proteins (redox
proteomics), phosphorylation (phosphoproteomics), ubiquitination (diglycine remnant proteomics), protein
fragmentation (degradomics), and other posttranslational modifications (PTMs). Many studies have linked these
PTMs to pathogenic mechanisms of neurodegeneration. To date, identifying PTMs on specific pathology-associated
proteins has proven to be a valuable step in the evaluation of functional alteration of proteins and also elucidates
biochemical and structural explanations for possible pathophysiological mechanisms of neurodegenerative diseases.
This review provides an overview of methods applicable to the identification and quantification of PTMs on proteins
and enumerates historic, recent, and potential future research endeavours in the field of proteomics furthering the
understanding of PTM roles in the pathogenesis of neurodegeneration.
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disease1. Introduction
Neurodegenerative diseases representing a diverse spec-
trum of disorders differ in molecular etiology and pro-
gression, as represented by Alzheimer’s disease (AD),
Parkinson’s disease (PD), dementia with Lewy bodies
(DLB), Huntington’s disease (HD), frontotemporal lobar
dementia (FTLD), amyotrophic lateral sclerosis (ALS),
and others. Such diseases present in patients as progres-
sively worsening symptoms, sometimes with overlap
between diagnoses such that they are ultimately and
unambiguously identified only by signature molecular
neuropathology found at autopsy. For example, cognitive
impairment, behavioral deficits, motor sensory dysfunc-
tion and other deficits can overlap due to degeneration
of specific neural circuits and underlying death and/or
dysfunction of neurons, glia, and/or vasculature. The
pathogenic mechanism resulting in the onset and pro-
gression of each disease is often associated with genetic
variants and mutations and interactions with environ-
mental impacts, lifestyle risk factors, and slowly evolving* Correspondence: alevey@emory.edu
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unless otherwise stated.molecular changes due to aging [1,2]. Despite the broad
range of neurodegenerative clinical and pathological
phenotypes, there are several common pathogenic
mechanisms. An emerging theme for most diseases is
the accumulation of misfolded peptide or protein aggre-
gation and aggregate deposition within areas of the cere-
bral cortex, basal ganglia, and/or spinal cord, although
the relationship between clinical phenotype and protein
dysfunction have not been completely elucidated thus
far [3,4]. Protein homeostasis and folding capacity,
sometimes referred to as proteostasis, has been sug-
gested as a possible common pathway that is progressively
dysregulated with aging and neurodegenerative pathogen-
esis [5,6]. Protein forms which emerge post-translationally
through modification of protein residues can have starkly
different properties due to a single post-translational modi-
fication (PTM), for example phosphorylation of Tau in
neurofibrillary tangles, or cleavage and PTM of amyloid
precursor protein (APP) to yield modified amyloid beta
peptides.
Mass spectrometry (MS) is an emerging platform de-
veloped to identify and quantify proteins and exact
mass/charge (m/z) shifts due to PTMs, of either intact
proteins, or peptides that derive from those proteins.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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profile complex protein mixtures as tens to hundreds of
thousands of peptides in bottom-up proteomics, and will
open the door to the identification of a billion estimated
proteoforms due to specific combinations of PTMs on
intact proteins across different cell types [7], which can
also be accessed with top-down MS approaches [8]. A
number of research avenues to investigate neurodegen-
eration at different levels [e.g. in tissue, subcellular and
biochemical fractions, and biomarkers in the extra-
cellular milieu, including plasma or cerebrospinal fluid
(CSF)] with a variety of specific proteomic methods have
been involved in successful biomarker discovery, drug
target development and elucidation of pathogenic mech-
anisms in the past 20 years [9-17]. The purpose of this
review is to first present an overview of general method-
ologies applicable to the study of post-translational mod-
ifications (PTMs) of proteins, and second, we provide
references which highlight the importance, perhaps cen-
tral, of PTMs in characterizing pathogenic processes of
neurodegeneration and imbalances in proteostasis.
2. Proteomic approaches geared toward PTM
identification and quantitation
2.1 Biophysical and biochemical separations
Biophysical and biochemical separations offer a means
of reducing complexity of protein samples prior to MS,
and of homing into PTMs in different cell types or com-
partments. Subcellular fractionation has been success-
fully employed to look at AD-associated differences in
blood derived [18,19] or brain tissue-derived membrane
proteomes [20] and at neuron-specific nuclear proteomesFigure 1 Workflows for PTM identification (ID) and quantification by
to these methods.from post-mortem brain arrived at after fluorescence acti-
vated cell sorting (FACS) [21]. Both membrane and nu-
clear proteomes are accessed through ultracentrifugation,
whereas other separations may involve microdissection or
other means of selective isolation of affected regional sam-
ples from tissue, such as laser capture of cells with high
aggregate protein burden analysed subsequently by MS
[22]. Biochemical strategies are also useful for purification
of detergent-resistant inclusions and/or plaques [23] which
can occur not only extracellularly, but also in the nucleus,
cytosol, or mitochondria under conditions ranging from
physiological to pathophysiological [24-26]. Thus, fraction-
ation of cells and tissue enables more sensitive MS detec-
tion for low abundance proteins and promises to open up
avenues for specific identification of PTMs isolated to cell
types and compartments (Figure 1).
2.2 Intact protein affinity purification
Affinity purification is an approach whereby proteins or
peptides can be enriched via a binding property or other
physical characteristic that allows selective interaction
with specific target(s). We first discuss a couple of affinity
approaches that purify intact proteins; these serve only as
examples of a number of approaches similar in principle.
2.2.1 Tandem ubiquitin binding entities access the ubiquitome
The ubiquitin-proteasome system is linked to many neu-
rodegenerative diseases as it plays an essential role in
clearance of many pathogenic proteins, and is discussed
in detail in the context of neurodegeneration in section 3.
Ubiquitination (or ubiquitylation) events are labile due to
their propensity to signal for protein degradation, makingMS. Inset black ovals with white text specify review sections pertaining
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(TUBEs) have been developed for the protection and en-
richment of ubiquitinated proteins. TUBEs have increased
affinity of up to 1000-fold for poly-ubiquitin chains over a
single ubiquitin binding associated (UBA) domain, and
protect ubiquitinated proteins from the disruption medi-
ated by both proteasome and de-ubiquitinating enzymes
[27,28]. Thus, TUBEs allow for the detection of relatively
low abundance ubiquitinated proteins that cannot be de-
tected with previous technologies. Some TUBEs also have
specificity for enrichment of proteins with specific
topologies of ubiquitin chains attached, and it is not
inconceivable that some may exist which have affinity
for mixed chains of ubiquitin and small ubiquitin-like
modifier (SUMO), where the latter protein and other
ubiquitin-like modifiers provide an even greater chal-
lenge for unambiguous identification of attachment
sites [29].
Generally, after TUBE-based enrichment of ubiquitin
or ubiquitin/SUMO proteins and tryptic preprocessing
of proteins into peptides, MS/MS is the ideal down-
stream application for identification of the attachment
site remnant diglycine tag that results from cleavage of
the attached C-terminus of ubiquitin to protein N-termini
or, more usually, to lysine residue side chains of peptides.
The diglycine tag from ubiquitin is left on both ubiquitina-
tion substrates and ubiquitin and SUMO residues them-
selves, in polyubiquitin or mixed ubiquitin/SUMO chains.
There are eight attachment sites for polyubiquitination on
ubiquitin itself (the best characterized being K48 and K63)
which can be monitored and quantified by tandem MS
(MS/MS) approaches [30-32], but tens of thousands of at-
tachment sites across the proteome have recently been
identified [33,34], albeit following a peptide affinity ap-
proach which we discuss below, rather than using TUBEs,
which nonetheless hold promise for this application.
There are also three commercially available polyubiquitin
chain-specific antibodies developed via phage display
which are capable of immunoprecipitation of intact
protein ubiquitin conjugates that can be used to profile
biologically distinct ubiquitination substrates and/or asso-
ciated ubiquitin linkages [35,36].
2.2.2 Lectin affinity chromatography for glycosylated proteins
Changes in glycosylation of proteins have been linked to
neurodegeneration and reviewed in the context of MS-
based methods in detail as recently as 2010, and an
inventory therein confirms that glycoproteins are par-
ticularly well represented in CSF and brain [37]. Com-
pared to traditional purification methods using gel
separation of proteins, lectin affinity chromatography for
glycosylated proteins is a method for the large-scale
identification of N-linked glycoproteins from complex
biological samples [38]. This approach yields indirectinformation on the glycan structure via lectin binding
specificity for structurally variable glycans attached to
glycoproteins; for example, concanavalin A (Con-A)
and wheat germ agglutinin have specificity for man-
nose and N-acetylglucosamine, respectively [39]. Thus,
lectin affinity chromatography represents a valuable tool
for glycoproteome studies, reducing sample complexity
and enriching glycoprotein content in samples prior to
their identification by MS. The numbers of peptides iden-
tified by this method with multiple glycosylated sites will
probably continue to increase with better instrumentation
[40]. Glycans, which do not easily fragment into identifi-
able MS/MS fingerprints, are usually cleaved by an en-
zyme such as peptide N-glycanase (PNGase), which
results in a 1 Da shift in the mass of asparagine residue at-
tachment sites, which are converted by the enzyme to as-
partate. This shift can be disambiguated as a glycan
attachment site rather than an asparagine deamidation
event by performing PNGase digestion in the presence of
heavy (18O) labelled water. Con-A [41] and wheat germ
agglutinin [42] have each been employed to look at
changes in glycoproteins of the hippocampus and inferior
parietal lobe in AD. It is worth noting that Con-A has a
large hydrophobic domain that, under certain circum-
stances, can bind non-glycosylated proteins, leading to
false positive identification of glycoproteins.
2.3 Derivatization based approaches
Derivatization can be used both to identify PTMs and
for quantitative proteomics, where often all peptides are
tagged chemically, usually with different stable isotope
labels detectable by MS or MS/MS [43]. We focus here
on the former class of approaches, but there is overlap
in these methods. Quantitative labelling approaches also
improve the accuracy and confidence of PTMs identified
across samples processed by MS with different labels.
Derivatization by multiplex isobaric tags for pooled ana-
lysis and quantitation of multiple samples in a single MS
run had been plagued by compression effects affecting
the quantitative accuracy until recently, when novel
MS3-based or other approaches solved the problem
[44,45]. A perfect demonstration of the overlap between
derivatization for both PTM identification and peptide-
level quantitation comes from Robinson and Evans, who re-
cently developed a novel workflow combining N-terminal
stable isotope labelled dimethyl tagging with isobaric tag-
ging on the C-terminal residue of LysC-derived peptides
for global peptide sample multiplexing and quantitation
[46], and adapted the approach to specifically derivatize an
amine group onto 3-nitrotyrosine modified residues on
amine-blocked peptides with the amine-reactive isobaric
tag in their original publication on this approach [47], for
which they coined the term “combined precursor isotopic
labelling and isobaric tagging” (cPILOT).
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Endogenous protein cleavage underlies the generation of
pathological amyloid peptides from amyloid precursor
protein, and other protein cleavage events are also
thought to play a role in neurodegeneration. Derivatiza-
tion is often used to chemically modify specific amino
acids in proteins prior to or after digestion, for example
to prevent cleavage by preparative proteolytic enzymes
(e.g. trypsin) used prior to MS and/or to alter the prop-
erties of residues on these peptides such that they can
be subjected to affinity purification or enrichment, and
also to improve the physical properties of the derivatized
peptide for detection by MS. In most MS workflows,
cysteine residues are routinely reduced and alkylated
with iodoacetamide or N-ethylmaleimide to improve the
identification rate of peptides including this residue. How-
ever, derivatization of other residues such as C-terminal
ends and carboxyl groups on acidic side chains of Asp and
Glu [48,49] or primary amines on N-terminal ends of pro-
teins and Lys side chains [50] has proven useful for the
affinity enrichment of such in vivo N-terminal and
C-terminal derived peptides. One approach has been
termed terminal amine isotopic labelling of substrates
(TAILS) [50]. Intact proteins are derivatized prior to pre-
parative proteolytic digestion by trypsin, followed by a
second, differential derivatization of enzyme-generated
neo-N- and C-termini with a tag that can be affinity de-
pleted by a binding matrix. The flowthrough peptides are
then analysed by MS and represent peptide identifications
of in vivo protein N- or C-termini, which can prove defini-
tive for the identification of proteolytic cleavage occurring
prior to isolation of the intact proteins. These approaches
have opened up exciting possibilities both for identifica-
tion of N-terminal PTMs such as cyclization and N- and
C-terminal truncation by endogenous peptidases, respect-
ively contributing to knowledge of the secretome [50] and
degradome [51,52].
2.3.2 Histone derivatization
Epigenetic mechanisms have been implicated in neuro-
degenerative diseases including HD and AD. Histones
store epigenetic information in the context of chromatin
and for this reason, are functionally and dynamically
decorated by a broad array of PTMs encompassing
many, if not most, of the full array of enzymatically-
derived PTMs [53]. Another application of derivatization
is the modification of pre-enriched histones, which can
be readily purified by affinity columns or even via ex-
traction in strong acids. Histones are propionylated on
N-termini and primary amines (Lys side chains) by pro-
pionic anhydride [54,55]. This protects lysine residues
from digestion by trypsin, and improves the mass/charge
ratio of the longer peptides which would otherwise have
too many positive charges if not for the chemicalmodification of positive charge-carrying primary amines
into charge-free amides. Because longer peptides are gen-
erated by this approach, analysis that incorporates MS
downstream is sometimes referred to as middle-down
proteomics. Analysis of histones in bulk from whole cell
chromatin averages the quantitative contribution of differ-
ent PTM-specific peptides found on different DNA locus-
specific regions of chromatin, thus the future of MS-based
identification of histone PTMs that implicate those PTMs
in regulation of specific DNA regions or genes will rely on
innovative approaches that are still under development as
they would apply to human samples [56,57] with limited
amounts of starting material [58].
2.3.3 Examples of other PTM-oriented approaches benefiting
from derivatization
Iodoacetamide, which alkylates cysteines at room tem-
perature, also di-alkylates lysine side chains at elevated
temperature, and this modification mimics the mass and
charge characteristics of the tryptic remnant of ubiquitin
attachment to lysine, diglycine [32], as mentioned above.
This property has been successfully applied to tag all
MS-accessible lysine residues of a purified protein
in vitro to generate standard peptide MS/MS finger-
prints of the protein to validate in vivo-generated ubi-
quitination attachment site peptides [59]. This is just
one example of how derivatization can be used in in-
novative approaches for MS identification and validation
of PTMs. In the future, it is foreseeable that derivatiza-
tion and affinity purification may be increasingly com-
bined to achieve purification and identification of novel
PTMs. One example follows.
Secretion of proteins from tissue, such as from the
brain into CSF, is a major source of biomarkers in living
subjects. Analysis by MS of proteins secreted from cells,
tissue, or organisms under certain physiological or patho-
logical conditions is referred to as secretomics. The secre-
tome typically incorporates PTMs such as signal peptide
cleavage, among others, and constitutes an important class
of proteins that control and regulate multiple physiological
processes such as endocrine, paracrine, and autocrine sig-
naling. This makes it a clinically relevant source for bio-
markers and therapeutic targets. Although promising,
most secretome studies were carried out using in vitro tis-
sue rather than in vivo [60]. In vitro, both contamination
by nonstandard secreted proteins and release of intracellu-
lar proteins contribute to the proteome detected [61].
However, derivatization shows promise in overcoming
these problems. As mentioned above, N-terminal peptide
derivatization for identification has been applied to the
secretome, and there is also a fascinating development re-
cently in a method called secretome protein enrichment
with click sugars (SPECS), which identified veritable
in vivo beta secretase substrates in brain [62], using exactly
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2.4 Identification by orthogonal parallel approaches, e.g.
oxyblot/MS
Oxidative stress resulting in oxidative damage of pro-
teins is a common event in neurodegeneration. A num-
ber of studies [63-73] utilize parallel detection by, for
example, two-dimensional polyacrylamide (2D-PAGE)
oxyblot analysis, in which carbonyl moieties (aldehydes
and especially ketones, both of which normally are not
present on proteins) are reacted with dinitrophenylhy-
drazine to form dinitrophenylhydrazone (DNP) adducts.
Then, following two-dimensional electrophoresis and
transfer to membrane, a DNP-recognizing antibody is
capable of detecting oxidation event(s) on one or more
protein spots, where each spot is thought to represent a
single, unique protein species. Then, in parallel analysis,
these studies proceed to identify the same gel spots from
a duplicate stained gel using MS [9]. Other versions of
this parallel detection approach have been applied to the
identification of, protein adducts occurring downstream
of lipid peroxidation, where Michael adducts of alpha,
beta-alkenal products of free radical mediated lipid per-
oxidation can attack proteins [69], and other modifica-
tions, such as advanced glycation end product protein
conjugates. Since these modifications of proteins occur
stochastically, and often on any of the 20 amino acid
residues—as is the case for carbonylation—with limited
site specificity as opposed to other PTMs which are
imparted with enzymatic specificity, the abundance of
any one chemically pure modification for detection by
MS is limited, and thus a “guilt by association” approach
may be the best available method for detection of these
PTMs. A parallel immunoblotting/MS approach has also
been used to examine proteins with high or enhanced 3-
nitrotyrosine in AD brain as early as 2003, whereby this
modification downstream of reactive nitrogen species
(RNS) was implicated in potential dysregulation of neur-
onal metabolism and neuropeptide signalling [74]; a
similar antibody against 3-nitrotyrosine can also affinity
purify proteins prior to MS analysis [53]. There is an ex-
ception to the above where a specific non-enzymatic
PTM can be directly detected by MS: methionine oxida-
tion to methionine sulfoxide occurs within the range of
physiological conditions, but oxidation and/or reductive
loss of this PTM may also occur during protein and pep-
tide processing steps, making it challenging to attribute
to conditions in vivo with certainty. Nonetheless, it has
been postulated that the microenvironment of cells af-
fected by neurodegeneration is susceptible to attack of
proteins and other molecules by reactive oxygen species
(ROS) or RNS, downstream of not only contextually
normal metabolic processes but also and especiallyfollowing exposure to environmental toxicity which may
precede loss of beneficial (or gain of toxic) function on
the part of the modified protein [75].
2.5 Peptide affinity purification
The principles of affinity purification have also been suc-
cessfully applied to the enrichment of specific PTM-
decorated peptides following preparative proteolysis,
thereby separating peptides which harbor the site of PTMs
from others, even those derived from the same protein
but lacking the PTM. Here we focus on one physicochem-
ical approach at enriching phosphopeptides and a more
general antibody-based approach at PTM-specific peptide
pre-enrichment prior to MS. Such enrichment approaches
are also envisioned to be useful protocols that could be
coupled to other downstream detection, identification
and/or quantitation methods.
2.5.1 Phosphopeptide enrichment
Kinase dysregulation resulting in protein phosphoryl-
ation is widely implicated in neurodegenerative mecha-
nisms, where extensive Tau phosphorylation preceding
polymerization downstream of a host of kinases is just
one example. Phosphorylated Ser, Thr, and Tyr residues
with a high negative charge density have a particular af-
finity for transition metal cation chromatographic resins,
such as germanium, titanium, niobium, hafnium, zirco-
nium, and iron [76,77]. Calcium chloride precipitation of
phosphopeptides has also been explored with some suc-
cess [78]. In a recent study, we employed immobilized
metal affinity chromatography (IMAC) using ferric chlor-
ide bound to nitrilotriacetic acid (NTA) beads to achieve
80% purity of phosphopeptides extracted and digested
from human post-mortem brain (Dammer et al., Proteo-
mics, in press). While this study identified over 5,000
phosphopeptides, other studies using phosphopeptide en-
richment prior to MS have identified well over 10,000
unique phosphosites across the proteome of a single cell
line or tissue [79-81]. Other studies have focused on a
smaller number of phosphosites in subcellular organelles,
such as mitochondrial, phosphoproteomes in different
tissues [82,83], or the kinome [84,85], which profiles func-
tionally relevant phosphosites, usually on kinases them-
selves. The kinase activity assay for kinome profiling
(KAYAK) approach has been recently optimized, even ob-
viating the need for IMAC enrichment prior to detection
and quantification of target kinome phosphopeptides [84].
2.5.2 Antibody-based PTM- and/or motif-specific peptide
affinity purification
To monitor how multiple critical signaling pathways are
altered under specific conditions, an immunoaffinity-
based enrichment step coupled to LC-MS/MS detection
and quantitation called PTMScan has been developed and
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and service by Cell Signaling Technologies. Thousands of
PTM-containing peptides from specific proteins partici-
pating in signaling pathways or specific protein types from
cell lines, tissues, or xenografts can be identified utilizing
the specificity of PTM- and/or motif-specific antibodies.
The method is also compatible with both SILAC and
label-free quantification. Thus far, target motifs include a
series of PTMs specific to modifications occurring in sig-
naling pathways, such as serine/threonine kinase specific
motifs, tyrosine kinase substrate motifs, the Akt/PI3K
pathway, lysine acetyltransferase substrates, and ubiquitina-
tion [86,87]. The PTMScan concept represents a powerful
quantitative method that is exceedingly adept at identifying,
for example, ubiquitin diglycine attachment site remnant
peptides via a specific antibody to enrich and purify tens
of thousands of unique modified peptides that result from
trypsin digestion of ubiquitinated proteins [33,34].
3. A proteomic perspective of neurodegeneration:
advances highlight PTMs in disease-defining
aggregates, implicating quality control (QC)
signalling and degradation deficits or gain
of function
Proteomic advances have elucidated the molecular identity
and specificity of different neurodegenerative diseases,
often by identifying the proteins which are misfolded and
thought to be—and often, later shown to be—toxic to cells
in the CNS either through gain or loss of function due to
the misfolding propensity of protein. PTMs regulate QC
of misfolded proteins, and both their aggregation and
clearance propensity [88]. Misfolding and aggregation are
not, however, synonymous [89]. The latter process can be
shown in certain cases to decrease toxicity of monomeric
and oligomeric misfolded proteins, and is often an actively
regulated process which relies on PTMs and related sig-
nalling prior to the deposition of PTMs, where aggrega-
tion can precede targeted degradation [90]. It is aggregates
and their PTMs which are most easily detected in neuro-
degenerative disease tissue, thus they are considered the
defining features of molecular pathology in neurodegener-
ative CNS [90]. In some cases, a PTM is obligate for the
formation of a specific protein aggregate, for example,
beta- and gamma- secretase cleavage of amyloid precursor
protein is widely thought to be a necessary prerequisite to
the formation of extracellular beta-amyloid-containing
plaques that are a hallmark of AD, but which do not con-
tain intact amyloid precursor protein, and rather only 40–
42 residues of post-translationally cleaved sequence [91].
3.1 Stress-related PTMs, protein misfolding and the
detergent resistant proteome
The cause(s) of protein misfolding [89] and its effects
are both considered as forms of stress to cells, often withparticular effects in specialized cells of the CNS. These
forms of stress can range from mutation of the gene for
the misfolding-prone (or aggregate prone) protein, aber-
rant signalling (often resulting in protein PTMs), metabol-
ite or metabolism by-product accumulation or deficiency,
or insufficient capacity to refold or clear toxic misfolded
proteins through degradation pathways [92,93]. These
stresses often overlap or feed forward, enhancing each
other and synergizing, accelerating decline in the function
or viability of cells particularly in the complex milieu of
CNS tissue, where many cells have extensive processes—
e.g. dendrites and axons of neurons—isolated away from
the cell body, which require local synthesis and transport
of essential factors to remain fully functional, and disease
associated proteins often have roles in these transport pro-
cesses [90]. Compounded stress results in higher aggrega-
tion propensity for an affected protein and also often
sequesters their usual, or novel, interaction partners. This
aggregation-prone response to stress of certain proteins
has been harnessed by some biological processes, for ex-
ample polysome/messenger RNA (mRNA) stress granule
formation, which is a response to oxidative or metabolic
stress that temporarily arrests housekeeping gene transla-
tion in favor of stress responsive transcript translation; it
happens that mRNA stress granule components contrib-
ute to detergent insoluble protein deposits in a number of
neurodegenerative diseases [94]. Aggregation propensity
of a protein is related to the ability of a structure to self-
organize, such as mRNA stress granules or paired helical
filaments including abundant tau protein in tauopathies,
but such structure formation may involve a number of
other protein and non-protein factors that have roles in
templating and supporting extensive aggregation, often
because they harbor intrinsically disordered regions with
exceptional, if not also conditional, aggregation propensity
[95] that can be modulated by PTMs such as phosphoryl-
ation [96]. The initial and complete identifications of the
makeup of aggregates in disease have been major hurdles
to progress in understanding how cells deal with stress,
where one measurable outcome of that stress is the mis-
folding and subsequent aggregation of select proteins. But
while protein aggregation is a signature of cellular stress
responses, following the detection and identification of
proteins in aggregates, an additional hurdle for researchers
is to further elucidate the often unclear function(s) of the
aggregate prone proteins and often, their associated intrin-
sically disordered domains which have thus been impli-
cated in stress responses. Other factors and proteins
which do not aggregate are also not excluded from im-
portant roles in stress response. However, aggregate prone
proteins are particularly relevant to pathogenesis because
in the case of proteinopathies which include AD, PD,
tauopathies, and diseases with RNA binding protein inclu-
sions, the aggregates are themselves pathogenic, in the
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ity and incidence to brain regions progressively affected
later during disease progression [97].
Historic milestones in publications implicating PTMs
in disease-specific protein aggregation abound. Phos-
phorylated, ubiquitinated, acetylated, or oxidized species
of pathogenic inclusions can partition differently into a
detergent insoluble (hereafter “insoluble”) biochemical
fraction, often with elevated levels in this insoluble frac-
tion. Phosphorylation of insoluble alpha synuclein found
in Lewy bodies of PD patients at a distinct residue
(Ser129) increases in vitro aggregate formation four-fold
[98], and can be deposited by a kinase genetically linked
to PD [99]. Paired helical filaments that make up neuro-
fibrillary tangles of affected neurons in AD are hyper-
phosphorylated and ubiquitinated [100], and recently
have been associated within soluble U1 spliceosome com-
ponents [23,101,102], in addition to classical hyperpho-
sphorylated tau with this phosphorylation reducing Tau
microtubule crosslinking character [103]. Lysine acetyl-
ation of Tau also occurs in the context of different peptide
motifs within, to either prevent [104], or enhance [105,106]
accumulation of insoluble Tau fibrils. The mRNA stress
granule protein TDP-43 is also hyperphosphorylated,
cleaved, ubiquitinated, and/or oxidized, all preferentially in
the insoluble fraction of neurodegenerative disease tissue
and cellular models of TDP-43 inclusion or aggregate for-
mation [59,107-109]. Amyloid precursor protein is itself
phosphorylated at T654, which is critical for subsequent
cleavage into amyloid beta in a cellular neuronal AD
model [110]; other PTMs occur on amyloid cleavage prod-
ucts, as well, including oxidation, phosphorylation, nitra-
tion, racemization, isomerization, pyroglutamylation, and
glycosylation–involved in different physiological and patho-
logical amyloid properties that may regulate disease
progression [111]. An unconventionally translated hexa-
nucleotide repeat expansion in C9ORF72 and mutant
prion-like hnRNPA2 in familial forms of ALS syndromes
also each contribute aggregate prone peptides to the insol-
uble fraction of select brain regions such as cerebellum
and hippocampus, where the inclusions are positive for
ubiquitin and ubiquitin binding proteins [112,113]. The
list in this paragraph is only representative, and by no
means exhaustive, of aggregate prone protein PTM par-
ticipation in insoluble aggregates found to be specific to
different neurodegenerative diseases.
3.2 Ubiquitination, key to most misfolded protein and
organelle QC mechanisms
Ubiquitin is an 8 kDa protein with a very stable fold re-
sistant to misfolding, which makes this and 17 other
ubiquitin-like protein folds which attach to substrates
[114]. Ideal tags that can be used to sort and regulate
misfolded or misfolding-prone proteins. Ubiquitin, SUMO,and interferon stimulated gene ISG15 are upregulated to
deal with cellular or systemic stress such as reactive
oxygen-induced misfolding of proteins, ER-associated
stress, or an increase in protein misfolding propensity
brought on during the heat shock response, whereas
others may have divergent, more specialized, roles for ex-
ample in signalling or enforcing enzymatic activity as does
NEDD8 neddylation of cell cycle-stage specific cullin-
ubiquitin ligase complexes, thereby activating substrate
specific ubiquitin ligase activities during cell division.
PTMs play a wide-ranging set of roles in QC, reviewed
recently by Wang, Pattison and Su [115]. A vast array
of ~600 ubiquitin ligases can deposit monoubiquitin or
polyubiquitin chains on lysine residues or N-termini of
tens of thousands of substrates across the human prote-
ome, and ~98 deubiquitinases (endoproteases or isopepti-
dases) reverse this process, edit polyubiquitin signals, and/
or recycle ubiquitin from its substrates [114] with dynam-
ics that regulate detection and marking of misfolded
protein, active refolding, sequestration of stubbornly mis-
folded proteins, and ultimately also as a fait accompli
mark on aggregates, misfolded proteins, and dysfunctional
whole organelles like mitochondria and peroxisomes, sig-
nalling their respective modes of destruction, thus limiting
toxicity of misfolded protein and maintaining proteome
and cell integrity via a cycle of protein QC interactions.
Deubiquitinases are essential for initial ubiquitin release
from multiple translation products of genes which encode
tandem ubiquitin fusions, implicating the central import-
ance of these along with ubiquitin in maintaining cellular
QC capacity essential for survival. There is an essential
hydrophobic patch on ubiquitin centered around Ile44,
which mediates (poly)ubiquitinated substrate recognition
and binding ubiquitin recognizing proteins, such as those
containing UBA domains [116], which are often found in
proteins that also harbor ubiquitin-like folds—thought to
self-modulate interactions with ubiquitinated substrates.
QC processes remain incompletely characterised due to
the many niches which proteins occupy in a cell during
their various life cycles and a division of labor between
QC [117] and signal-dependent protein degradation—
which targets correctly folded proteins at the time their
function or activity must end such as during progression
through the cell cycle. Despite this, much progress has
been made by studying conserved QC mechanisms in
eukaryotic systems with a very well characterized prote-
ome, such as yeast—though often directly implicating
roles for ubiquitin mediated protein QC and ubiquitin re-
cycling in neurodegeneration. Invariably, the life cycle of a
protein begins with co-translational quality control as any
nascent polypeptide forms and exits the ribosome
[118-120], and ends with terminal sequestration in insol-
uble aggregates or—more often in cells able to survive—
degradation and recycling of components at the lysosome
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ation systems. Ubiquitinated substrate degradation by the
26S proteasome relies on K48-linked polyubiquitin con-
taining at least 4 ubiquitin moieties [121], but can utilize
other unconventionally assembled polyubiquitin chains
[32]. Proteasome insufficiency in neurons is enough to
cause neurodegeneration and results in characteristic in-
clusions such as ALS-like Bunina bodies, Lewy body-like
inclusions reminiscent of PD, and can exacerbate HD
pathology [122-124]. Ubiquitin recycling which regulates
ubiquitinated substrate degradation rate via a proteasome-
associated deubiquitinase, Usp14, is also essential for
maintenance of healthy synapses [125], where synaptic
damage has come to define AD and PD pathogenesis
[126], often downstream of glutamatergic dysregulation.
For example, excitatory amino acid transporter has been
shown to accumulate in biochemically insoluble lesions in
AD, correlating with cognitive decline [127]. The enigmatic
but abundant ubiquitin carboxy-terminal hydrolase also
with potential ubiquitin ligase activity known as UCH-L1
was shown to be prone to oxidative modification(s) in AD
brain in pioneering work by Castegna et al. [128]. This
change may upset the activit(ies) of UCH-L1 such that the
net balance of free-to-conjugated ubiquitin, or of edited
ubiquitin linkages, is disrupted in AD brain [30].
Lysosomal targeting of cellular cargo into double-
membrane enclosed autophagosomes uses a protein with
an ubiquitin-like fold, light chain 3 (LC3) that is trans-
ferred to the autophagosome membrane via acyl (phos-
phatidylethanolamine) conjugation in a process that is
reminiscent to ubiquitin activation (E1), conjugation
(E2), and ligase (E3) activities. Following this, LC3 deco-
rated preautophagosome membranes and monoubiquitin
or ubiquitin chains on autophagosomal cargo are
bridged by proteins like NBR1 or p62/sequestosome
[129,130], and then the mature, membrane enclosed,
autophagosomeis fused with acidified vacuoles which ul-
timately mature into a cellular lysosome. Ubiquitinated
substrate receptors like p62 can compete with or pos-
sibly cooperate with the proteasome for ubiquitinated
substrate binding and degradation [131], but ubiquitin
targeted autophagy appears to preferentially use K63-
linked polyubiquitin chains, in addition to monoubiqui-
tination, and K63 ubiquitination has been implicated in
neurodegeneration [30,132]. Autophagosomes which do
not successfully degrade in lysosomes recapitulate gran-
ulovacuolar degeneration phenotypes seen in neurode-
generative disorders, particularly AD [133]. NBR1- and
p62-positive pathology are also hallmarks of various in-
soluble protein deposits in neurodegeneration [134,135].
Monoubiquitin attachment to select proteins displayed
on mitochondria or peroxisomes also can be a sufficient
signal for the autophagosomal targeting and degradation
of these organelles [136]. The ubiquitination site specificityand topology of Parkin-dependent target modification in
response to mitochondrial depolarization in PD has been
examined using peptide affinity capture coupled to MS,
revealing extensive conservation of Parkin-dependent ubi-
quitination sites on cytoplasmic domains in mitochondrial
outer membrane proteins [137], consistent with a role for
these residues in enabling mitophagy following a mito-
chondrial permeability transition [138]. Of note, direct
substrate ubiquitination is excluded from some targeted
degradation pathways involved in clearing misfolded pro-
teins such as chaperone mediated autophagy, but there
are a limited number of such substrates intrinsically de-
fined by primary sequence motifs that regulate protein life
span in conjunction with misfolding that may expose these
often buried motifs [115]. Like the number of enzymes in-
volved in ubiquitination, the cellular QC field is vast, and
we refer the reader to reviews highlighted in this section
for thorough coverage [92,114,115,117,139].
3.3 Signalling through receptors and kinase cascades, the
secretome and roles of protein cleavage
We use the term signalling here in the context of pathways
relevant to neurobiological function including, but not
limited to: neuronal excitation- or activity-responsiveness,
signalling between organs or within the CNS such as
through endocrine or neuro-peptides, responsiveness to
metabolite or nutrient availability, cellular growth, differ-
entiation, extended cellular process formation, mRNA
transport and mRNA translation to protein in such pro-
cesses, glial responsiveness to changing tissue conditions
in the CNS, inflammation, and last, broad programs of
transcriptional regulation which can be a retrograde ef-
fector, if not also upstream of any of the above signal-
dependent stimuli and responses. Rather than exhaustively
reviewing the literature on this subject, we only touch on
examples which have been put forward through the in-
novative use of proteomic approaches centered on PTMs
or enzymes imparting PTMs that are likely to expand in
their number of applications, use, and importance in com-
ing years. For example, the first proteomic analysis of
phosphorylated proteins in AD brain (hippocampus) was
performed by Di Domenico et al. in 2011, finding that 17
proteins involved in neuronal energy metabolism and sig-
nalling pathways were significantly altered [140].
Neurotrophic signalling and activity-based stimulation
of changes in the PTM status of downstream target pro-
teins represent mediators of both neuronal outgrowth or
axons and dendrites, and of memory consolidation. For
example, following brain derived neurotrophic factor
(BDNF) or Wnt stimulation of receptors on neurons, or
as a quick response following neuronal depolarization,
cyclic AMP-response element binding (CREB) protein is
phosphorylated at Ser133 [141], promoting retrograde
signalling to the nucleus via nuclear translocation and
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genes and with histone acetyltransferases like CREB
binding protein CBP and other transcriptional coactiva-
tors, thereby promoting target transcription and local
translation (confirmed by proteomics [142]) required for
long term memory consolidation. O-GlcNAc modifica-
tion of CREB Ser40 was discovered and found to be a
central regulator in this process using enzymatic label-
ling of GlcNAc-terminated proteoglycan chains with a
2 kDa polyethylene glycol tag to enable detection of the
PTM by Western blot, and confirmation was performed
using electron transfer dissociation (ETD) MS, followed
by numerous experiments elucidating an inhibitory role
in neurite outgrowth, fear conditioning, and antagonism
of coregulator binding to CREB [141]. An approach
using azido-tagged sugar enzymatic modification of
O-glycosylated peptides prepared for MS has also been
described [143] and should gain in use by MS labs focused
on this PTM in the future. O-GlcNAc also extensively
modifies Tau [144] and this modification hinders aggrega-
tion [145]. Of note, O-GlcNAc modifications occur due to
hyperglycemic conditions in diabetes, which is a major
risk factor for AD, and this PTM crosstalks with various
other PTMs, particularly phosphorylation [146]. SUMO-
ylation has been shown to be activity dependent in the
neuronal synaptosomal fraction, modifying numerous pro-
teins and promoting glutamate receptor internalization
and endosomal cycling downstream of long term potenti-
ation [147], thus unbiased interrogation of SUMOylation
substrates in synaptosomes by proteomic methods is
warranted. Other modifications including acylation (e.g.
palmitoylation of growth associated protein 43) play im-
portant but incompletely defined roles in learning and
memory [148], awaiting developments in proteomic ap-
proaches that target these PTMs. Tubulin is a very abun-
dant protein making transport possible and providing the
cytoskeleton which co-forms with neuronal processes, and
PTMs have been extensively characterized in neurons, lo-
calized to different functional domains in the cell [149].
Recently, a novel PTM, polyamination, was detected by
MS on tubulin from axons, deposited by transglutaminase
[150]. Thus, neurons and synapses harbor a wealth of
PTMs that greatly expand the repertoire of protein func-
tions beyond directly encoded transcript sequence in
genes, and many of these PTMs are likely as yet un-
detected and uncharacterized, but we predict will be found
to play important roles in neuronal function, especially
learning and memory.
Secretion of protein and peptide factors that affect
processes and downstream PTMs in signalling throughout
the CNS is also a major area of intense experimentation,
because CSF is an accessible source of proteinaceous sam-
ple for prognostic, diagnostic, and therapeutic biomarkers
in neurodegeneration patients. Above, we mentioned theSPECS method, which was applied to identify 34 beta
secretase BACE1-derived substrates from primary cells
[62]. Automated MS interrogation of the secretome is also
becoming a reality [151]. Secreted peptides derive from
targeted proteolytic cleavage, thus, proteolysis is also a key
regulatory PTM of interest in normal and pathological
processes in the brain. Proteolysis plays a role in diverse
cellular processes including programed cell death, im-
mune function, and development. There are many crucial
proteins and their cleaved fragments aggregate in neuro-
degeneration [152], however, the mechanism underlying
the proteolytic processing of many proteins remains un-
clear. Therefore, unbiased methods employed toward an
understanding of degradomics [52], for identifying prote-
ase substrates and tracking the extent of cleavage, are
sorely needed for furthering our understanding of the
pathogenesis of neurodegeneration. Recently, Herskowitz
et al. analyzed post-mortem human brain using a forward
and reverse (in vitro) MS-based approach to find that
asparaginyl endopeptidease (AEP) directly cleaves TDP-43
at seven sites, two of which were found in FTLD brain
tissue [153].
From the field of chemical proteomics, activity based
probes have become powerful tools for characterizing
distinct protease activity, targeting only the protease(s)
that are active against a specific substrate [154]. This ap-
proach has been coupled to a MS readout [155], and fo-
cuses on identifying the source of specific cleavage
events which may be unknown in a given cell or tissue
context, rather than often well-established cleavage tar-
gets. Natural product small molecules, metabolites and
drugs can also be engineered to generate protein adducts
which are suitable for determining pharmacological pro-
tein targets using an activity based probe approach
[156], which promises to open up mechanistic under-
standing of drug-protein interactions in neurodegenera-
tion and other fields.
4. Future perspective
While a battery of proteomic approaches are available to
quantitatively analyse PTMs on tens of thousands of tar-
gets, the functional alteration that PTMs engender re-
quires a larger toolbox of experimental approaches
which demand the combination of MS based approaches
with more diverse methods, in order to go beyond sim-
ple PTM and protein identification and quantification.
For example, despite the progress in methods in the last
10 years relating to histone PTMs highlighted in an
above section, reports of histone modification differ-
ences in the context of native chromatin from different
cell types of neurodegenerative disorders using unbiased
MS approaches is hard to find. Methods which couple
biophysical and biochemical separation of histones and/
or nuclei [21] to histone PTM identification in the brain
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biology of chromatin modifications that occur globally
and/or in a locus-specific fashion at specific genes or
chromosomal regions. In the future, we plan to carry out
studies of epigenetic alterations in brains of individuals
with AD, MCI, and FTLD. PTMs including oxidation,
phosphorylation, ubiquitination and proteolysis all re-
quire further study in experiments that hold great prom-
ise for the elucidation of pathogenic mechanisms of
neurodegeneration. Application of the technologies we
have outlined are essential tools for the systematic, if not
unbiased, study of neurodegenerative disorders, and
promise to reveal multiple mechanisms of pathological
protein aggregation and identify therapeutic targets in
the future.
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